Original Title: Acute Limb Ischemia and Outcomes With Vorapaxar in Patients with Peripheral Artery Disease: Results From TRA2°P-TIMI 50. Reference: Marc P. Bonaca et al. Circulation. 2016 Mar 8;133(10):997-1005. Patients with peripheral artery disease have a high risk of acute limb ischemia, an event that may result in the loss of the affected limb. This<a href="https://solaci.org/en/2016/03/14/vorapaxar-in-acute-limb-ischemia/" title="Read more" >...</a>
Original Title: Impact of diabetic status on outcomes after revascularization with drug-eluting stents in relation to coronary artery disease complexity. Reference: Koskinas KC et al. Circ Cardiovasc Intv. 2016; Epub ahead of print Diabetic patients ongoing PCI with drug eluting stents (DES) are at higher risk of repeat revascularization than non-diabetic patients. According to this<a href="https://solaci.org/en/2016/02/22/diabetes-has-higher-impact-on-des-outcomes-than-disease-complexity/" title="Read more" >...</a>
Original Title: Safety and efficacy of everolimus-versus sirolimus-eluting stents: 5-Year results from SORT OUT IV. Reference: Jensen LO et al. J Am Coll Cardiol. 2016;67:751-762. Reassuring long term outcomes from SORT OUT IV confirm the safety and efficacy of second generation everolimus eluting stents (EES) over first generation DES. The difference at 5-year follow up<a href="https://solaci.org/en/2016/02/17/sort-out-iv-at-5-years-second-generation-des-efficacy-confirmed/" title="Read more" >...</a>
Original Title: One-year Clinical and Computed Tomography Angiographic Outcomes after Bioresorbable Vascular Scaffold Implantation during Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction. The Prague-19 Study. Reference: Widimsky P et al. Circ Cardiovasc Interv. 2015 Dec;8(12). Courtesy of Dr. Carlos Fava. Primary PCI is the most common course of treatment for ST elevation myocardial infarction (STEMI)<a href="https://solaci.org/en/2016/02/15/primary-pci-with-bioresorbable-vascular-scaffolds/" title="Read more" >...</a>
Long-Term Outcomes with First vs. Second-Generation Drug-Eluting Stents in Saphenous Vein Graft Lesions. Nagendra R. Pokala. Catheterization and cardiovascular Intervention 2016;87:34-40 Courtesy of del Dr. Carlos Fava. Second generation DES have been proved superior to first generation DES in native arteries, but there is limited information on DES in saphenous vein grafts (SVG), from a<a href="https://solaci.org/en/2016/02/12/in-saphenous-vein-graft-lesions-1st-and-2nd-generation-des-have-similar-outcomes/" title="Read more" >...</a>
Original Title: Drug-eluting balloon versus second-generation drug-eluting stent for the treatment of restenotic lesions involving coronary bifurcations. Reference: Toru Naganuma et al. EuroIntervention 2016;11:989-995 Courtesy of del Dr. Santiago F. Coroleu. PCI involving in-stent restenosis (ISR), especially in coronary bifurcations, is associated with high rates of recurrent restenosis and the need for new revascularization. Although drug<a href="https://solaci.org/en/2016/02/10/drug-eluting-balloon-vs-second-generation-des-for-restenotic-lesions-in-bifurcations/" title="Read more" >...</a>
Original Title: Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial CME. Reference: Ricardo A. Costa et al. J Am Coll Cardiol Intv. 2016;9(1):51-64. The purpose of this study was to assess the efficacy and long<a href="https://solaci.org/en/2016/01/26/polymer-free-biolimus-coated-stent-5-year-outcomes/" title="Read more" >...</a>
Courtesy of Dr. Agustín Vecchia. The aim of this study was to compare the safety and efficacy of bioresorbable everolimus eluting scaffolds (BVS) vs. everolimus eluting stents (EES) in patients with ischemic heart disease. Medline, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), was searched for scientific sessions, abstracts, and relevant websites for<a href="https://solaci.org/en/2016/01/19/meta-analysis-of-bioresorbable-vascular-scaffolds-vs-everolimus-eluting-stents/" title="Read more" >...</a>
Original Title: “Long-term outcomes of routine versus provisional T-stenting for de novo coronary bifurcation lesions: five-year results of the Bifurcations Bad Krozingen I study”. Authors: Miroslaw Ferenc, MD; Mohamed Ayoub, MD; Hans-Joachim Büttner, MD; Michael Gick, MD; Thomas Comberg, MD; Jürgen Rothe, MD; Christian M. Valina, MD; Willibald Hochholzer, MD; Franz-Josef Neumann, MD. Division of Cardiology and<a href="https://solaci.org/en/2015/12/28/long-term-outcomes-of-routine-vs-provisional-t-stenting-for-de-novo-coronary-bifurcations-five-year-outcomes-of-the-bbk-i-trial/" title="Read more" >...</a>
Original Title: Benefits and Risks of Extended Dual Antiplatelet Therapy after Everolimus-Eluting Stents. For the Dual Antiplatelet Therapy (DAPT) Study Investigators. Reference: James B. Hermiller et al. JACC: Cardiovascular Interventions 2015, online before print. The DAPT study had shown that continued aspirin plus thienopyridine beyond a year reduces ischemic events. Given the fairly low rate of thrombosis<a href="https://solaci.org/en/2015/12/11/dual-antiplatelet-therapy-after-everolimus-eluting-stenting/" title="Read more" >...</a>